Microneedle Patch
Microneedle patches are increasingly recognized as an attractive drug delivery platform because they may enable minimally invasive, potentially painless self-administration while reducing sharps waste, improving convenience and supporting better patient adherence. They may also offer advantages such as room-temperature stability, avoidance of first-pass metabolism and customizable release profiles, making them appealing across pharmaceutical, diagnostic, wellness and cosmetic applications.
PatchPRINT™
PharmaTher is advancing microneedle patch innovation with PatchPRINT™, its proprietary mobile 3D printing platform. PatchPRINT™ aims to integrate a purpose-built 3D printer, compliant formulations, and an AI-driven engine for scalable, tailored microneedle patches for drug delivery, diagnostics, and personalized remedies. PharmaTher intends to use PatchPRINT™ for its own product portfolio and to offer partners product development, manufacturing, and platform integration services across research, commercial, defence, and humanitarian sectors.
Prototype rendering of PatchPrint™, PharmaTher’s automated tabletop microneedle patch production platform designed for end-to-end manufacturing.
The Company has submitted a provisional patent application to the United States Patent and Trademark Office (“USPTO”) for PatchPrint™, its Automated Tabletop Microneedle Patch 3D Printer. The application is titled “Automated Tabletop Microneedle Patch Printer with Integrated Demolding, Packaging, and Multi-Product Cargo-Adaptive Processing” (Application No. 64/015,408).
PharmaPATCH™
PharmaPATCH™: Proprietary Microneedle Delivery Platform
PharmaPATCH™ is a proprietary microneedle-enhanced delivery system designed to provide an efficient, minimally invasive, and potentially painless method for delivering drug candidates, including psychedelics, peptides, and other medicines. The microneedle patch technology is based on a novel biocompatible and biodegradable gelatin methacryloyl (“GelMA”) material intended to enable delivery of both water-soluble and water-insoluble compounds with customizable release profiles. The GelMA-based microneedle array is designed to penetrate the stratum corneum (outer layer of the skin) and supports flexible drug-loading capacity, including potential combinations, microdosing, and controlled-release delivery. Microneedles are widely considered a promising approach to achieve systemic drug exposure via transdermal delivery while potentially avoiding absorption limitations and first-pass metabolism associated with oral administration. PharmaPATCH™ is also intended to support at-home self-administration and incorporates anti-tampering and anti-abuse features. The Company has completed research studies demonstrating PharmaPATCH™ feasibility for delivering psychedelic compounds, including ketamine, DMT, psilocybin, MDMA, and LSD.
PharmaPATCH™ is a proprietary microneedle-enhanced delivery system designed to provide an efficient, minimally invasive, and potentially painless method for delivering drug candidates, including psychedelics, peptides, and other medicines. The microneedle patch technology is based on a novel biocompatible and biodegradable gelatin methacryloyl (“GelMA”) material intended to enable delivery of both water-soluble and water-insoluble compounds with customizable release profiles. The GelMA-based microneedle array is designed to penetrate the stratum corneum (outer layer of the skin) and supports flexible drug-loading capacity, including potential combinations, microdosing, and controlled-release delivery. Microneedles are widely considered a promising approach to achieve systemic drug exposure via transdermal delivery while potentially avoiding absorption limitations and first-pass metabolism associated with oral administration. PharmaPATCH™ is also intended to support at-home self-administration and incorporates anti-tampering and anti-abuse features. The Company has completed research studies demonstrating PharmaPATCH™ feasibility for delivering psychedelic compounds, including ketamine, DMT, psilocybin, MDMA, and LSD.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."
The proposed PharmaPatch™ products are strictly for research use only and are not intended for human cosmetic or therapeutic applications at this time.
The proposed PharmaPatch™ products are strictly for research use only and are not intended for human cosmetic or therapeutic applications at this time.
Connect With Us
PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario Canada
M5C 1P1
82 Richmond Street East
Toronto, Ontario Canada
M5C 1P1
© COPYRIGHT 2026. PharmaTher Holdings Ltd. ALL RIGHTS RESERVED.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."